CELCUITY INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 7 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-06-10: Reporting owner Murphy Polly A.; Form 4; Security Stock Option (right to buy); Transaction G Bona fide gift.
- 2026-06-10: Reporting owner Murphy Polly A.; Form 4; Security Stock Option (right to buy); Transaction G Bona fide gift.
- 2026-06-10: Reporting owner Buller Richard E; Form 4; Security Stock Option (right to buy); Transaction G Bona fide gift.
- 2026-06-10: Reporting owner Buller Richard E; Form 4; Security Stock Option (right to buy); Transaction G Bona fide gift.
CELC insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-10 | Murphy Polly A. Director | 4 | Stock Option (right to buy) Derivative · Direct · (m) | G Bona fide gift | −14,048 0 owned after | $10.69 exercise price | $88.24 | 2026-06-12 |
| 2026-06-10 | Murphy Polly A. Director | 4 | Stock Option (right to buy) Derivative · Indirect · (m) | G Bona fide gift | +14,048 14,048 owned after | $10.69 exercise price | $88.24 | 2026-06-12 |
| 2026-06-10 | Buller Richard E Director | 4 | Stock Option (right to buy) Derivative · Direct · (m) | G Bona fide gift | −12,503 0 owned after | $10.69 exercise price | $88.24 | 2026-06-12 |
| 2026-06-10 | Buller Richard E Director | 4 | Stock Option (right to buy) Derivative · Indirect · (m) | G Bona fide gift | +12,503 12,503 owned after | $10.69 exercise price | $88.24 | 2026-06-12 |
| 2026-06-02 | Laing Lance G. Director, Officer (Chief Science Officer) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,000 20,250 owned after | $9.89 exercise price | $91.42 | 2026-06-04 |
| 2026-05-04 | Buller Richard E Director | 4 | Stock Option (right to buy) Derivative · Indirect · By Trust | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,000 654 owned after | $5.10 exercise price | $144.98 | 2026-05-06 |
| 2026-03-31 | Buller Richard E Director | 4 | Stock Option (right to buy) Derivative · Indirect · By Trust | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 9,654 owned after | $5.10 exercise price | $114.14 | 2026-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |